Genetic polymorphisms influencing therapy and susceptibility to rejection in organ allograft recipients

BioDrugs

Volumn 16, Issue 1, 2002, Pages 11-17

  Poli, Francesca ^a   Piccolo, Giuseppe ^a   Scalamogna, Mario ^a  

^a FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

6 THIOINOSINIC ACID; AZATHIOPRINE; AZATHIOPRINE DERIVATIVE; BREQUINAR; CHEMOKINE; CORTICOSTEROID; CYCLOPHILIN; CYCLOSPORIN; CYTOKINE; DRUG METABOLITE; FK 506 BINDING PROTEIN; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 6; LEFLUNOMIDE; MERCAPTOPURINE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS; THIOPURINE METHYLTRANSFERASE; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

BONE MARROW SUPPRESSION; CANCER; CHRONIC DISEASE; CORONARY ARTERY DISEASE; DISEASE PREDISPOSITION; DRUG INDUCED DISEASE; GENETIC POLYMORPHISM; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; HUMAN; IMMUNOGENETICS; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIPID METABOLISM; LUNG TRANSPLANTATION; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REVIEW;

EID: 0036230732     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200216010-00002     Document Type: Review

References (72)

1. The Unos Scientific Renal Transplant Registry: Ten years of kidney transplants
2. Studies on condensed pyrimidine systems. IX. Synthesis of some 6-substituted purines
3. Prolonged survival of human kidney homografts by immunosuppressive drug therapy
4. The mode of action of immunosuppressive agents
5. Chronic allograft vasculopathy: New strategies for drug development
6. Early versus late acute renal allograft rejection: Impact on chronic rejection
7. Chronic graft rejection
8. Long-term results of cardiac transplantation
9. Antibody-mediated rejection following cardiac transplantation
10. Chronic remodelling pathology in grafts
11. Infection in organ-transplant recipients
12. World-wide thoracic organ transplantation: A report from UNOS/ISHLT international registry for thoracic organ transplantation
13. Cancer report. Australia and New Zealand dialysis and transplant registry
14. Cancer in immune-suppressed organ transplant recipients: Aetiology and evolution
15. Single base polymorphism in the human tumor necrosis factor alpha (TNF alpha) gene detectable by Ncol restriction of PCR product
16. The effect of cytokine gene polymorphisms on paediatric heart allograft outcome
17. Investigation of the polymorphism in the interleukin-10 gene promoter
18. In vitro production of IFN-gamma correlates with CA repeat polymorphism in the human IFN-gamma gene
19. The effect of novel polymorphism in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis
20. Genetic regulation of cytokine synthesis: Consequences on acute and chronic organ allograft rejection
21. Cytokine gene polymorphisms and relevance to forms of rejection
22. Cytokine gene polymorphisms predict acute graft rejection following renal transplantation
23. Analysis of the polymorphism of the tumor necrosis factor (TNF) gene and promoter and of circulating TNF-alpha levels in heart-transplant patients suffering or not suffering from severe rejection
24. Expression of tumor necrosis factor-alpha gene during allograft rejection following rat liver transplantation
25. Immunomodulatory properties of recombinant murine and human tumor necrosis factor
26. The biology of cachectin/TNF: A primary mediator of the host response
27. Human tumor necrosis factor alpha gene regulation by virus and lipopolysaccharide
28. Human tumor necrosis factor alpha gene regulation in phorbol ester stimulated T and B cell lines
29. Genetic analysis of the human tumor necrosis factor alpha/cachectin promoter region in a macrophage cell line
30. Tumor necrosis factor-alpha m-RNA accumulation in human myelomonocytic cell lines. Role of transcriptional regulation by DNA sequence motifs and mRNA
31. Interactive effects of the tumor necrosis factor promoter and 3′-untranslated regions
32. A new cluster of genes within the human major histocompatibility complex
33. Enhancers and transcription factors controlling the inducibility of the tumor necrosis factor-alpha promoter in primary macrophages
34. Gene polymorphism at position -308 of the tumor-necrosis-factor-alpha (TNF-alpha) in multiple sclerosis and it's influence on the regulation of TNF-alpha production
35. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription
36. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation
37. A genetic association between systemic lupus erythematosus and tumor necrosis factor alpha
38. Tumor necrosis factor alpha gene polymorphisms and rheumatic diseases
39. Genetics of tumor necrosis factor (TNF) in autoimmune liver diseases: Red hot or red herring?
40. Variation in the TNF alpha promoter region associated with susceptibility to cerebral malaria
41. Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis
42. Interleukin-6 and its receptor: A paradigm for cytokines
43. Impaired immune and acute-phase responses in interleukin-6-deficient mice
44. Interleukin IL-6 directs the differentiation of IL-4 producing CD4+ T cells
45. The absence of IL-6 does not affect Th2 cell development in vivo, but does lead to impaired proliferation, IL-2 receptor expression, and B cell responses
46. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory response
47. Interleukin-6 and neopterin in renal transplant recipients. A longitudinal study
48. Interleukin-6 expression after renal transplantation
49. Patterns of graft infiltration and cytokine gene expression during the first 10 days of kidney transplantation
50. Serum and urine IL-6 and TNF-alpha in renal transplant recipients with graft dysfunction
51. Donor cytokine genotype influences the development of acute rejection after renal transplantation
52. B7-1 expression of Langerhans cells is upregulated by proinflammatory cytokines, and is down-regulated by interferon-gamma or by interleukin-10
53. Structure of the mouse IL-10 gene and chromosomal localisation of the mouse and human genes
54. Isolation of the human interleukin 10 promoter. Characterisation of the promoter activity in Burkitt's lymphoma cell lines
55. Interleukin-10 eliminates anti-CD3 monoclonal antibody-induced mortality and prolongs heart allograft survival in inbred mice
56. The effect of polymorphisms in tumor necrosis factor-α, interleukin-10, and transforming growth factor β1 genes in acute hepatic allograft rejection
57. Association of polymorphisms in the human interferon-γ and interleukin-10 gene with acute and chronic kidney transplant outcome
58. Cytokine gene polymorphism and heart transplant rejection
59. Cellular responses to interferon-gamma
60. Genotyping for polymorphism in interferon-gamma, interleukin-10, transforming growth factor-beta 1 and tumour necrosis factor alpha genes: A technical report
61. Genotypic variation in the transforming growth factor-beta 1 gene: Association with TGF-β1 production fibrotic lung disease and graft fibrosis after lung transplantation
62. Mercaptopurine pharmacogenetics: Monogenic inheritance of erythrocyte methyltransferase activity
63. Thiopurine methyltransferase activity in American white subjects and black subjects
64. Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphism
65. Altered mercaptopurine metabolism, toxic effects, and dosage requirement thiopurine methyltransferase-deficient child with acute lymphocytic leukaemia
66. Congenital thiopurine methyltransferase deficiency and 6-mercaptopurine during treatment for acute lymphoblastic leukaemia
67. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient
68. Azathioprine-induced myelosuppression in thiopurine methyltransferase deficient heart transplant recipient
69. The importance of thiopurine methyltransferase activity for the use of azathioprine in transplant recipients
70. Transplantation
71. Searching for genetic determinants in the new millennium